Business Wire

VECIMA/VECTOR/LIBERTY

17.5.2021 14:02:57 CEST | Business Wire | Press release

Share
Vecima Networks and Vector Technologies Enable Gigabit Services for Liberty Global

Liberty Global (NASDAQ: LBTYA, LBTYB and LBTYK), one of the world’s leading converged video, broadband and communications companies, continues the rollout of Remote PHY (R-PHY) technology in Europe, with the support of Vector Technologies and Vecima Networks Inc. (TSX: VCM). The partnership will start Liberty Global on a path to delivering 10Gbps connectivity throughout their European footprint.

The jointly developed, next-generation R-PHY solution packages Vecima’s Entra ERM112 RPD (Remote PHY Device) module in Vector Technologies’ ACCERON Compact R-PHY Node. The fully interoperable solution accelerates deployment of Distributed Access Architecture (DAA) in Liberty Global's access network and enables Liberty Global to fulfil their 10G network roadmap, delivering the next great leap in speed, capacity, and low latency.

“The partnership with Vecima and Vector Technologies was a natural extension of our ongoing business activities, mainly focused on our mission to create the next-generation broadband networks in Europe,” said Seamus Gallagher, Liberty Global’s VP of Access Network Strategy. “Currently, we have over 19 million homes connected throughout Europe with speeds of 1Gbps. DAA brings many benefits, such as increased network bandwidth and less equipment in the headend and hub by enabling a multi-service - video/data/voice/mobile backhaul - unified, fiber core network. We are excited to continue our gigabit rollout with a solution that helps avoid vendor lock-in and supports multi-vendor interoperability.”

Liberty Global, with support from Vecima and Vector Technologies, plans to complete field trials in Autumn 2021 in their Western and Central Europe operating companies. The trials showcase R-PHY’s operational efficiency and the planned deployment cement Liberty Global as a worldwide leader in next-gen gigabit broadband.

‟We are excited to partner with both Liberty Global and Vector Technologies to leverage our Entra DAA solutions to transform consumer experiences in homes, businesses, and anywhere that people connect,” said Clay McCreery, Chief Operating Officer at Vecima. “Utilizing existing network infrastructures, Vecima is committed to building and delivering the industry’s most innovative cable access solutions that will deliver ground-breaking speed and capacity. Liberty is one of the leading operators in the world, and we’re proud to help enable their strategic vision.”

Liberty Global requirements included a solution that was fully interoperable with their deployed CCAP Core platforms. The Vecima ERM112 RPD module gives Liberty Global the freedom to source access network elements from multiple vendors, enhancing cost efficiency and accelerating time to market. Vector Technologies acted as the integrator for the project and performed all necessary tests at its DAA and DOCSIS laboratories.

"Vector Technologies and Vecima built a solution that supports a standards-based, multi-vendor environment. We believe that openness is the key to building the access network of the future, and we are committed to building scalable, secure, and simple solutions to manage network solutions that avoid vendor lock-in scenarios," said Maciej Muzalewski, CTO of Vector Technologies. We performed all the essential tests at our high-tech laboratories, which we built to support future DOCSIS and DAA implementations. We are delighted to continue our partnership with Liberty Global as an integrator, helping them forge ahead to gigabit speeds across their footprint."

Bridging the new 10G digital fiber CIN networks and the legacy RF coax plant, the combined Vector Technologies and Vecima solution supports architectures that push fiber deeper into the network, allowing operators to leverage existing network capacity and deliver increased bandwidth to subscribers.

About Liberty Global

Liberty Global (NASDAQ: LBTYA, LBTYB and LBTYK) is one of the world’s leading converged video, broadband and communications companies, with operations in seven European countries under the consumer brands Virgin Media, Telenet, UPC, the combined Sunrise UPC, as well as VodafoneZiggo, which is owned through a 50/50 joint venture. Our substantial scale and commitment to innovation enable us to invest in the infrastructure and digital platforms that empower our customers to make the most of the digital revolution.

Liberty Global delivers market-leading products through next-generation networks that connect customers subscribing to 50 million broadband, video, fixed and mobile telephony services across our brands. We also have significant investments in ITV, All3Media, ITI Neovision, LionsGate, the Formula E racing series and several regional sports networks.

For more information, please visit www.libertyglobal.com .

About Vecima Networks

Vecima Networks Inc. (TSX: VCM) is a global leader focused on developing integrated hardware and scalable software solutions for broadband access, content delivery, and telematics. We enable the world’s leading innovators to advance, connect, entertain, and analyze. We build technologies that transform content delivery and storage, enable high‑capacity broadband network access, and streamline data analytics.

Further information about Vecima’s Entra solution is available at https://vecima.com/solutions/distributed-access/ . Or visit our website at www.vecima.com .

About Vector Technologies
Vector Technologies acts as a European competence center for the world’s largest Multiple System Operators and support them in network transformation towards Distributed Access Architecture.

As an experienced partner, we:

  • integrate, optimize and design solutions for Next Generation Access Networks
  • define the best directions of technological development in the area of Distributed Access Architecture (DAA) or Passive Optical Networks (PON) and Software-Defined Networking (SDN)
  • support Multiple System Operators in the efficient technology migrations
  • help operators in increasing efficiency and availability of provided services
  • have proven field experience in managing turnkey projects for Remote-PHY, DAA, DOCSIS 3.1 and DOCSIS 3.0

For more information, updates and useful links, please visit our website: https://vectortechnologies.com/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye